Immunomodulators as adjunctive therapy for HIV-1 infection

Journal of Clinical Virology

Volumn 22, Issue 3, 2001, Pages 289-295

  Pett, S L ^a   Emery, S ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adjuncts; HIV; IL 2; Immunotherapy; Interleukin 2

Indexed keywords

ANTIRETROVIRUS AGENT; IMMUNOMODULATING AGENT; INTERLEUKIN 2; VIRUS RNA;

AREA UNDER THE CURVE; BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENCE; IMMUNOMODULATION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; META ANALYSIS; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; MALE; RNA, VIRAL; VIRAL LOAD;

EID: 0034843021     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(01)00201-3     Document Type: Conference Paper

References (55)

1. IL-2 therapy produces no change in HIV RNA after 1 year
2. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤250 cells/μl CD4 T-cells and undetectable plasma virus load
3. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp 160 as a therapeutic vaccine in early stage HIV-1 infected volunteers
4. Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy
5. + patients
6. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA panel
7. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
8. Outpatient continuous intravenous interleukin-2 or subcutaneous, polyethylene glycol modified interleukin-2 in human immunodeficiency virus-infected patients: A randomized, controlled, multicenter study
9. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipdaemia, and diabetes mellitus: A cohort study
10. A syndrome of lipoatrophy, lactic-acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor related lipodystrophy syndrome
11. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
12. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
13. + T cell repertoire that are not immediately restored by antiviral or immune-based therapies
14. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type-1-infected persons
15. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type-1 infection
16. Immunologic and virologic effects of subcutaneous interleukin-2 in combination with antiretroviral therapy: A randomised controlled trial
17. Dynamics of HIV replication and persistence in the CNS after antiretroviral therapy
18. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease
19. Randomised study of intermittent subcutaneous interleukin-2 (IL-2) therapy without antiretrovirals versus no treatment
20. Randomized trial of MN rgp 120 HIV-1 vaccine in symptomless HIV-1 infection
21. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
22. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
23. Indinavir not nelfinavir is associated with systemic hypertension when compared to no protease inhibitor therapy
24. Toward HIV eradication or remission: The tasks ahead
25. Latent reservoir and residual HIV-1 replication on antiretroviral therapy
26. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells
27. Sustained increases in CD4 counts with intermittent interleukin-2 therapy in HIV-infected patients with greater than 200 CD4 cells per cubic millimeter
28. Effects of intermittent interleukin-2 therapy on plasma and tissue human immunodeficiency virus levels and quasi-species expression
29. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-infected subjects
30. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomized controlled trial
31. 3
32. Highly active antiretroviral therapy in a large urban clinic
33. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men
34. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
35. + lymphocytes as prognostic markers of HIV-1 infection
36. Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: Results from the Euro-SIDA study
37. 3: ACTG 328 - Final results at 84 weeks
38. + lymphocyte counts and the risk of progression to AIDS
39. Applications of poxvirus vectors to vaccination: An update
40. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
41. Interleukin-2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism
42. A randomized, controlled 24-week study of intermittent subcutaneous interleukin-2 in HIV-1 infected patients in Thailand
43. A syndrome of lipodystrophy in patients receiving stable nucleoside-analogue therapy
44. Duration of Proleukin IL-2 therapy is more important than total dose in achieving CD4 expansion
45. Longer term immunologic effects and side-effects of successful antiretroviral therapy
46. Interleukin-2: Inception, impact and implications
47. Antiviral and immunological effects of interleukin-2 during quadruple-drug combination therapy in early HIV-1 infection
48. Close out of four phase II vanguard trials and patient roll-over into a large international phase III HIV clinical endpoint trial
49. Human services panel on clinical practice for treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents
50. Molecular characterisation of interleukin-2
51. Recovery of replication competent HIV despite prolonged suppression of plasma viraemia
52. Randomised study of intermittent subcutaneous interleukin-2 (IL-2) therapy without antiretrovirals versus no treatment (UK IL-2 Vanguard to the ESPRIT study)